Cover Image


Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 299174
出版日期 內容資訊 英文 39 Pages
Back to Top
Clozaril(精神分裂症):市場預測與分析 Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 39 Pages

Clozapine屬於dibenzazepine系的精神用藥,由Novartis以「Clozaril」「Leponex」的品牌名、Jazz Pharmaceuticals以「FazaClo」(口含錠(ODT)劑型)推出上市。這個醫藥品受體結合機制獨特,Clozaril託其受體選擇性之福,一般認為對二種類持續型抗精神病(其中至少一種為非典型)無效的患者,及有持續自殺傾向的患者將有所作用。


第1章 目錄

第2章 簡介

  • 分析概要
  • 相關分析
  • 預定發行的相關分析

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理
  • 症狀

第4章 疾病的管理

  • 診斷
    • 主觀的評估
    • 疾病的分類
  • 治療方法概要
    • 治療精神分裂症相關的急性激越症狀
    • 精神分裂症的維持療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 關於Clozaril(Clozapine)

  • 概要
  • 阻力性精神分裂症的治療藥的功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄


Product Code: GDHC357DFR

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Clozapine belongs to the dibenzazepine class of psychotropics and it is marketed under the brand names Clozaril and Leponex by Novartis, and FazaClo (an ODT formulation) by Jazz Pharmaceuticals. The drug is unique in its receptor-binding profile: thanks to its receptor selectivity, Clozaril should be considered in patients who fail to respond to two consecutive antipsychotics (one of which should be atypical) and in patients who display persistent suicidality.


  • Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Clozaril including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Clozaril for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Clozaril performance
  • Obtain sales forecast for Clozaril from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
    • 4.1.1. Subjective Assessments
    • 4.1.2. Disease Subtypes
  • 4.2. Treatment Overview
    • 4.2.1. Treatment of Acute Agitation Associated with Schizophrenia
    • 4.2.2. Maintenance Treatment of Schizophrenia

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Clozaril (clozapine)

  • 6.1. Overview
  • 6.2. Efficacy in Treatment-Resistant Schizophrenia
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosis and Treatment Rates
    • 7.4.2. Adherence Rates
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Key Opinion Leaders
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Reviewers
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptom Clusters of Schizophrenia
  • Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis
  • Table 3: Development-Based Classification of Antipsychotic Drugs
  • Table 4: Receptor Binding Profiles of Atypical Antipsychotics
  • Table 5: Guidelines for the Treatment of Schizophrenia
  • Table 6: Leading Branded Treatments for Schizophrenia, 2013
  • Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014
  • Table 8: Product Profile - Clozaril
  • Table 9: Clozaril SWOT Analysis, 2014
  • Table 10: Global Sales Forecast ($m) for Clozaril, 2012-2022
Back to Top